ArriVent BioPharma | 4:持股变动声明-董事 Hohneker John
ArriVent BioPharma | 3:首次持股声明-董事 Hohneker John
ArriVent BioPharma | 4:持股变动声明-董事 Peterson Kristine
ArriVent BioPharma | 3:首次持股声明-董事 Peterson Kristine
ArriVent BioPharma | SC 13G:超过5%持股股东披露文件-Yi Shi(6.4%),LAV Fund VI, L.P. (“LAVVI”)(6.2%)等
ArriVent BioPharma | SC 13D:超过5%持股股东披露文件-OrbiMed Advisors LLC(9.1%),OrbiMed Capital GP VIII LLC(4.5%)等
ArriVent BioPharma | 4:持股变动声明-股东 HILLHOUSE INVESTMENT MANAGEMENT, LTD.
ArriVent BioPharma | 4:持股变动声明-董事 ORBIMED ADVISORS LLC
ArriVent BioPharma | 4:持股变动声明-董事 HEALY JAMES
ArriVent BioPharma | 4:持股变动声明-董事 GORDON CARL L
ArriVent BioPharma | 4:持股变动声明-董事 Jallal Bahija
ArriVent BioPharma | 4:持股变动声明-董事 Nolet Chris
ArriVent BioPharma, Inc. | 3:首次持股声明-股东 HILLHOUSE INVESTMENT MANAGEMENT, LTD.
ArriVent BioPharma, Inc. | 3:首次持股声明-董事 ORBIMED ADVISORS LLC
ArriVent BioPharma, Inc. | 3:首次持股声明-高管 Yao Zhengbin
ArriVent BioPharma, Inc. | 3:首次持股声明-董事 Nolet Chris
ArriVent BioPharma, Inc. | 3:首次持股声明-高管 Lutzker Stuart
ArriVent BioPharma, Inc. | 3:首次持股声明-高管 LaChapelle Robin
ArriVent BioPharma, Inc. | 3:首次持股声明-高管 Kung Winston
ArriVent BioPharma, Inc. | 3:首次持股声明-高管 Kastenmayer James Paul
暂无数据